Eikon Therapeutics(EIKN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EIKN Eikon Therapeutics

Trading 10-23 10:02:29 EDT

7.74

-0.50

-6.02%

High8.07	Low7.74	Vol37.10K
Open8.07	D1 Closing8.24	Amplitude3.96%
Mkt Cap418.05M	Tradable Cap136.67M	Total Shares53.98M
T/O291.47K	T/O Rate0.21%	Tradable Shares17.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":7.744,"timestamp":1792764100894,"preClose":8.24,"halted":0,"volume":37095,"delay":0,"changeRate":-0.06019417475728161,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"Trading","change":-0.496,"latestTime":"10-23 10:02:29 EDT","open":8.07,"high":8.07,"low":7.744,"amount":291471.276822,"amplitude":0.039563,"askPrice":7.78,"askSize":10,"bidPrice":7.7,"bidSize":57,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792785600000},"marketStatusCode":2,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":8.24,"preHourTrading":{"tag":"盘前","latestPrice":8.24,"preClose":8.24,"latestTime":"09:20 EDT","volume":253,"amount":2085.2891234999997,"timestamp":1792761623949,"change":0,"changeRate":0,"amplitude":0.083738},"postHourTrading":{"tag":"盘后","latestPrice":8.24,"preClose":8.24,"latestTime":"19:47 EDT","volume":3183,"amount":26227.92,"timestamp":1792712871493,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.03872},"requestUrl":"/m/hq/s/EIKN/tweets","defaultTab":"tweets","newsList":[{"id":"2677927216","title":"Eikon Therapeutics Reports 26.4% Response Rate for Eik1003-Paclitaxel Combination in Phase 1/2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2677927216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677927216?lang=en_us&edition=fundamental","pubTime":"2026-10-23 21:16","pubTimestamp":1792761399,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics Reports 26.4% Response Rate for EIK1003-Paclitaxel Combination in Phase 1/2 TrialEikon Therapeutics presented early-stage cancer trial results for EIK1003, EIK1004 and EIK1005 at th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nNDL6zVn7h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014039.USD","BK4585","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","BK4139","SG9999014013.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","NDAQ","SG9999014005.SGD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","BCDF","SG9999014021.USD","EIKN","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677920834","title":"Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2677920834","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677920834?lang=en_us&edition=fundamental","pubTime":"2026-10-23 21:15","pubTimestamp":1792761300,"startTime":"0","endTime":"0","summary":"Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/23/3387290/0/en/eikon-therapeutics-presents-data-from-parp1-selective-and-wrn-helicase-programs-at-the-european-society-for-medical-oncology-congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","KBWY","EIKN","ORR","BK4213","SD","BK4139","FXN","BK4218","EPV","CR","PK","PR","WRN","BK4161","BK4168","PXI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676857669","title":"Eikon Therapeutics to present abstracts on clinical candidates at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2676857669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676857669?lang=en_us&edition=fundamental","pubTime":"2026-10-19 07:05","pubTimestamp":1792364705,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-to-present-abstracts-on-clinical-candidates-at-esmo-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-to-present-abstracts-on-clinical-candidates-at-esmo-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EIKN","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676575139","title":"Eikon Therapeutics Releases Updated Phase 2 Lung Cancer Trial Abstract Ahead of ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2676575139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676575139?lang=en_us&edition=fundamental","pubTime":"2026-10-19 06:06","pubTimestamp":1792361203,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics Releases Updated Phase 2 Lung Cancer Trial Abstract Ahead of ESMOEikon Therapeutics will present seven abstracts covering four cancer drug candidates at ESMO in Madrid, beginning Oc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261018:nNDL73J9gn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014021.USD","NDAQ","SG9999014039.USD","LU0314104364.USD","EIKN","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","BCDF","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BK4585","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676575163","title":"Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2676575163","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676575163?lang=en_us&edition=fundamental","pubTime":"2026-10-19 06:05","pubTimestamp":1792361100,"startTime":"0","endTime":"0","summary":"Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/18/3382951/0/en/eikon-therapeutics-announces-availability-of-seven-abstracts-for-presentation-at-the-european-society-for-medical-oncology-congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139","EPV","BK4168","WRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676514537","title":"Eikon Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2676514537","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676514537?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:35","pubTimestamp":1792182900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675599711","title":"HC Wainwright Initiates Coverage on Eikon Therapeutics With Buy Rating, $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2675599711","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675599711?lang=en_us&edition=fundamental","pubTime":"2026-10-16 19:27","pubTimestamp":1792150073,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) has an average rating of overweight and mean price target of $25.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595869","title":"Eikon Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675595869?lang=en_us&edition=fundamental","pubTime":"2026-10-16 18:12","pubTimestamp":1792145545,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nAZN4TPFLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675769587","title":"Eikon Therapeutics Files IND for Prostate Cancer Drug EIK1006","url":"https://stock-news.laohu8.com/highlight/detail?id=2675769587","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675769587?lang=en_us&edition=fundamental","pubTime":"2026-10-15 21:11","pubTimestamp":1792069860,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics  submitted an investigational new drug application to the US Food and Drug Administration to evaluate EIK1006 for advanced metastatic prostate cancer, the company said Thursday.EIK1006 is a novel androgen receptor antagonist designed to target wild-type and clinically relevant receptor variants while maintaining favorable pharmaceutical properties, Eikon said.The company will assess whether the drug candidate's properties can deliver clinical benefits for patients with advanced prostate cancer, it added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675584029","title":"Eikon Therapeutics submits EIK1006 IND application to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2675584029","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675584029?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:20","pubTimestamp":1792066823,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the treat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-submits-eik1006-ind-application-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-submits-eik1006-ind-application-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","EIKN","LABU","BK4139","BK4585","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675581087","title":"Eikon Therapeutics Submits Ind for Novel Androgen Receptor Antagonist Eik1006 in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675581087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675581087?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:00","pubTimestamp":1792065637,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nFWN4611ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675346938","title":"Is Eikon Therapeutics (NASDAQ:EIKN) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2675346938","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675346938?lang=en_us&edition=fundamental","pubTime":"2026-10-14 19:03","pubTimestamp":1791975788,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eikn/eikon-therapeutics/news/is-eikon-therapeutics-nasdaqeikn-in-a-good-position-to-inves","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eikn/eikon-therapeutics/news/is-eikon-therapeutics-nasdaqeikn-in-a-good-position-to-inves","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QDTE","QQQY","TECS","QID","QQQE","TQQQ","QYLG","TQQY","03086","NDX","QQQA","EIKN","JEPQ","IYW","QQQJ","NVIW.SI","MNQmain","SQQQ","BK4139","PSQ",".IXIC","NQmain","QLD","QQQM","FTEC","QQQ","GPIQ","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666730998","title":"Major Investor Makes Bold Move on Eikon Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666730998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666730998?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:06","pubTimestamp":1788919582,"startTime":"0","endTime":"0","summary":"New insider activity at Eikon Therapeutics, Inc. ( ($EIKN) ) has taken place on September 8, 2026. Significant shareholder Column Group GP IV LP ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-on-eikon-therapeutics-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-makes-bold-move-on-eikon-therapeutics-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666637712","title":"Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666637712","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666637712?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:34","pubTimestamp":1788899655,"startTime":"0","endTime":"0","summary":"Column Group IV GP reports purchase of 89,200 Eikon Therapeutics shares valued at $1.03 millionColumn Group IV GP reported a purchase of 89,200 Eikon Therapeutics common shares at USD 11.56.Indirect holdings reported at 4,312,139 shares via Column Group IV, 1,319,164 via Column Group Opportunity III, 148,840 via Column Group IV-A.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL9sNLXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Column Group IV GP Reports Purchase of 89,200 Eikon Therapeutics Shares Valued at $1.03 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487978","title":"Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487978","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487978?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:32","pubTimestamp":1788435147,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics names Ching-Pin Chang as chief scientific officerEikon Therapeutics named Ching-Pin “CP” Chang executive vice president, chief scientific officer.Chang joins from Bristol Myers Squi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL9l9Cns:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU1839511570.USD","LU1057294990.SGD","IE00B64PRP62.GBP","LU0109394709.USD","BMY","LU2360032135.SGD","IE00BQXX3C00.GBP","LU0321505868.SGD","LU2087621335.USD","LU1291159041.SGD","NDAQ","LU1585245621.USD","LU0965509010.AUD","LU0306807586.USD","LU1093756168.USD","LU0859254822.USD","LU2125154778.USD","EIKN","LU0114720955.EUR","BBH","BMED","LU2242652126.USD","TBXU","IE00BQXX3D17.EUR","LU2242646821.SGD","LU1236620834.HKD","BK4585","GILD","LU1934455194.USD","SG9999014021.USD","IE00BKPKM429.USD","LU1093756325.SGD","IHE","MEDI","LU2133065610.SGD","BIB","IE00BN0W2V16.EUR","FTXH","LU0122379950.USD","LU1023059063.AUD","LU1983299246.USD","IBB","LU2095319765.USD","LU1718418525.SGD","LU0267386448.USD","BCDF","BK4550","TMED","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887923","title":"Eikon Therapeutics Appoints Ching-Pin Chang, M.d., Ph.d. as Executive Vice President and Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887923","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA3N4SRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664781879","title":"Press Release: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664781879","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664781879?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435000,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\"Eikon\"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715602","title":"Eikon Therapeutics Joins Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715602","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715602?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:31","pubTimestamp":1787743864,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics joins Cantor Global Healthcare Conference fireside chatEikon Therapeutics will join the 12th Annual Cantor Global Healthcare Conference in New York on Sept. 10, 2026 at 2:10 p.m. ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLVTLCl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2133065610.SGD","LU0267386448.USD","IE00BQXX3C00.GBP","LU0106261372.USD","BK4112","KBWB","LU0098860793.USD","LU0795875086.SGD","LU0795875169.SGD","SG9999014005.SGD","BCDF","LU0912757837.SGD","LU1244550494.USD","LU1244550221.USD","BK4588","LU0158827948.USD","LU1791710400.SGD","SG9999014039.USD","LU0971096721.USD","LU1064131342.USD","BK4581","LU2089283258.USD","LU0390134368.USD","BK4127","LU2028103732.USD","EIKN","LU1074936037.SGD","LU1720051017.SGD","IAI","IE00BGHQF748.EUR","LU2095319765.USD","BK4534","IE00BN0W2W23.USD","LU2271345857.HKD","IE00B3QW5Z07.USD","IE00BKVL7J92.USD","LU0210528500.USD","LU0314104364.USD","IE00BZ1G4Q59.USD","LU1732799900.SGD","LU0882574139.USD","BK4516","LU0557290698.USD","NDAQ","LU1720051108.HKD","LU1363072403.SGD","LU2487616109.SGD","LU0320765646.SGD","IE00BN0W2T93.GBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662157667","title":"Eikon Therapeutics to Participate in Investor Conferences in September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662157667","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662157667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:30","pubTimestamp":1787743800,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., Aug.  26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351236/0/en/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449477","title":"Eikon CEO Perlmutter Joins Cantor Fitzgerald KOL Webcast on PARP Inhibitors in Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660449477?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:15","pubTimestamp":1787084118,"startTime":"0","endTime":"0","summary":"Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncologyEikon Therapeutics will join a Cantor Fitzgerald-hosted KOL event on Aug. 20, 2026 at 9:00 a.m. ET.Chairman and C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLQxCq8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","SG9999014013.SGD","BK4112","IE00BQXX3F31.USD","LU2210150020.SGD","IE00BQXX3D17.EUR","LU2210149790.SGD","BK4588","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","EIKN","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","IE00BKPKM429.USD","BK4139","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eikontx.com","stockEarnings":[{"period":"1week","weight":0.0928},{"period":"1month","weight":-0.0824},{"period":"3month","weight":-0.0742},{"period":"6month","weight":-0.1466},{"period":"1year","weight":-0.5422},{"period":"ytd","weight":-0.5422}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eikon Therapeutics, Inc. was incorporated in Delaware on July 9, 2019. It is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, primarily in oncology. The leadership team has a notable track record of successfully developing impactful drugs. The company's strategy leverages a proprietary technology platform to create novel therapies, with lead candidates targeting serious diseases such as advanced melanoma and non-small cell lung cancer.","exchange":"NASDAQ","name":"Eikon Therapeutics","nameEN":"Eikon Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eikon Therapeutics(EIKN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eikon Therapeutics(EIKN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eikon Therapeutics,EIKN,Eikon Therapeutics股票,Eikon Therapeutics股票老虎,Eikon Therapeutics股票老虎国际,Eikon Therapeutics行情,Eikon Therapeutics股票行情,Eikon Therapeutics股价,Eikon Therapeutics股市,Eikon Therapeutics股票价格,Eikon Therapeutics股票交易,Eikon Therapeutics股票购买,Eikon Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eikon Therapeutics(EIKN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eikon Therapeutics(EIKN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction